Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 42,784,390 | 40,275,703 | 21,630,486 | 28,196,461 | 43,792,707 | 176,679,747 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 42,784,390 | 40,275,703 | 21,630,486 | 28,196,461 | 43,792,707 | 176,679,747 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 160,638 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 176,519,109 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 42,784,390 | 40,275,703 | 21,630,486 | 28,196,461 | 43,792,707 | 176,679,747 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 1,590,672 | 1,538,331 | 1,252,653 | 1,025,000 | 1,328,141 | 6,734,797 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 2,097,498 | 1,822,760 | 858,301 | 354,316 | 1,345,688 | 6,478,563 |
| 11 | Total support. Add lines 7 through 10 | 189,893,107 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2017 | (b) 2018 | (c) 2019 | (d) 2020 | (e) 2021 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2021 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2021 |
(iii) Distributable Amount for 2021 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2021 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2021: | ||||
| a From 2016....... | ||||
| b From 2017....... | ||||
| c From 2018....... | ||||
| d From 2019....... | ||||
| e From 2020....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2021 distributable amount | ||||
|
i
Carryover from 2016 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2021 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2021 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2021, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2021. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2022. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2017..... | ||||
| b Excess from 2018..... | ||||
| c Excess from 2019..... | ||||
| d Excess from 2020..... | ||||
| e Excess from 2021..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | MISCELLANEOUS - 2017 AMOUNT: $ 396. 2018 AMOUNT: $ 1,267. 2019 AMOUNT: $ 165. 2020 AMOUNT: $ 6,557. 2021 AMOUNT: $ 18,851. LIST RENTALS - 2017 AMOUNT: $ 2,793. 2018 AMOUNT: $ 170. 2019 AMOUNT: $ 2,201. 2020 AMOUNT: $ 0. 2021 AMOUNT: $ 0. COMMISSIONS - 2017 AMOUNT: $ 48,094. 2018 AMOUNT: $ 25,294. 2019 AMOUNT: $ 18,379. 2020 AMOUNT: $ 28,456. 2021 AMOUNT: $ 26,730. SPECIAL EVENTS - 2017 AMOUNT: $ 2,043,540. 2018 AMOUNT: $ 1,794,170. 2019 AMOUNT: $ 836,855. 2020 AMOUNT: $ 318,000. 2021 AMOUNT: $ 1,298,675. STORE SALES - 2017 AMOUNT: $ 2,675. 2018 AMOUNT: $ 1,859. 2019 AMOUNT: $ 701. 2020 AMOUNT: $ 1,303. 2021 AMOUNT: $ 1,432. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART III, LINE 1 | THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: - RESEARCH TO EXPLORE SCIENTIFIC APPROACHES TO HIV PREVENTION, TREATMENT, AND POTENTIAL CURES, AND TO ENHANCE THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV/AIDS; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; - EDUCATIONAL INITIATIVES TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PUBLISH UPDATES ABOUT THE LATEST MEDICAL, SCIENTIFIC, AND PREVENTION ADVANCES FOR PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC. |
| FORM 990, PART III, LINE 4A | WITH A $148,500 GRANT, KEITH JEROME, M.D., PH.D., OF THE UNIVERSITY OF WASHINGTON IN SEATTLE, WILL STUDY WHETHER OR NOT THE PRESENCE OF ART MIGHT ADVERSELY IMPACT THE EFFICACY OF ONE OF THE MOST WIDELY USED MEANS OF DELIVERING GENE THERAPY-ADENO-ASSOCIATED VIRUS (AAV). INDIVIDUALS WHO RECEIVE GENE THERAPY MOST LIKELY WILL BE TAKING ART, SO THE QUESTION OF COMPATIBILITY IS A VITAL ONE. THE RECIPIENT OF A FY2022 TARGET GRANT, ANJIE ZHEN, PH.D. (SEE ABOVE), WILL USE A $210,000 ARCHE GRANT TO CONTINUE TO FINE-TUNE CAR T CELL THERAPY, WHICH HAS SHOWN LIMITED SUCCESS AGAINST HIV TO DATE. DR. ZHEN WILL CREATE STEMS CELLS USING BLOOD-DERIVED STEM CELLS, SELECTED FOR THEIR POTENTIAL TO PERSIST AND SELF-RENEW. SHE WILL EXPLORE THEIR CAPACITY TO MATURE INTO NOT ONLY CAR T CELLS, BUT ALSO CAR-NATURAL KILLER CELLS AND CAR-MACROPHAGES, ALL THREE OF WHICH HAVE THE POTENTIAL TO ATTACK HIV-INFECTED CELLS. MATHILDE KRIM FELLOWSHIPS THE RECIPIENTS OF THE 2022 MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH - DR. SEBASTIAN FUCHS OF THE UNIVERSITY OF MIAMI IN FLORIDA, DR. LEILA GIRON OF THE WISTAR INSTITUTE IN PHILADELPHIA, AND DR. JEANNETTE TENTHOREY OF THE FRED HUTCHINSON CANCER RESEARCH CENTER IN SEATTLE - WERE ANNOUNCED IN MARCH. ANTIBODIES ARE A PROMISING TREATMENT OR POTENTIAL COMPONENT OF A CURE FOR HIV, BUT THEY ARE EXPENSIVE AND MUST BE DOSED REPEATEDLY. GERMAN-BORN DR. FUCHS AND HIS MENTOR DR. RON DESROSIERS HAVE BEEN WORKING ON A GENE THERAPY APPROACH TO DELIVERING THE INSTRUCTIONS FOR MAKING SPECIFIC ANTIBODIES SO THAT A PERSON'S BODY COULD MAKE AN INDEFINITE SUPPLY OF THEM. ONE CHALLENGE IS THAT THE IMMUNE SYSTEM CAN GENERATE RESPONSES AGAINST THESE ANTIBODIES AND DESTROY THEM BEFORE THEY CAN EXERT THEIR BENEFICIAL EFFECTS. DR. FUCHS WILL ATTEMPT TO INDUCE IMMUNE TOLERANCE OF THE FOREIGN ANTIBODIES BY EITHER REPEATEDLY EXPOSING THE IMMUNE SYSTEM TO THE ANTIBODIES THEMSELVES, OR BY RECRUITING RED BLOOD CELLS TO CONVEY A MESSAGE OF TOLERANCE TO THE IMMUNE SYSTEM. HIS RESULTS MAY IMPROVE OUR ABILITY TO DELIVER ANTIBODIES AS THERAPY NOT ONLY FOR HIV, BUT ACROSS A WIDE RANGE OF DISEASES. A NATIVE OF BRAZIL, DR. LEILA GIRON, SEEKS TO ANALYZE THE ROLE OF CELL METABOLISM IN HIV PERSISTENCE. DR. GIRON HAS DATA SUGGESTING THE PROCESS OF CELL METABOLISM CAN AFFECT THE ABILITY OF THE VIRUS TO REACTIVATE, AND THAT SOME COMPONENTS OF THE PROCESS CAN EVEN PREDICT WHETHER, AND FOR HOW LONG, A PERSON CAN CONTROL HIV WITHOUT ANTIRETROVIRAL THERAPY. SHE PLANS TO DELVE INTO THE RELATIONSHIP BETWEEN THIS METABOLIC PROCESS AND THE ABILITY TO CONTROL HIV. DR. TENTHOREY'S RESEARCH FOCUSES LARGELY ON TRIM5ALPHA, AN ANTIVIRAL PROTEIN THAT RESTRICTS HIV. AS A KRIM FELLOW, DR. TENTHOREY WILL INVESTIGATE FURTHER THE PROCESS THROUGH WHICH TRIM5ALPHA BINDS TO HIV AND ALTERS THE UNCOATING PROCESS NECESSARY FOR A VIRUS TO INFECT A CELL. WHILE HIV HAS EVOLVED TO AVOID THE ACTION OF TRIM5ALPHA, BETTER UNDERSTANDING THIS PROCESS COULD LEAD TO THERAPIES THAT WOULD ALLOW THE HUMAN BODY TO BLOCK THE VIRUS. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. ALEKSANDAR ANTANASIJEVIC, PH.D., OF THE COLE POLYTECHNIQUE FDRALE DE LAUSANNE, SWITZERLAND, WAS AWARDED $50,000 TO CONTINUE THE WORK FUNDED BY HIS 2021 KRIM FELLOWSHIP. HE IS USING A SOPHISTICATED IMAGING TECHNOLOGY CALLED CRYOEMPEM TO ADDRESS THE OBSTACLES THAT MAKE DEVELOPING AN HIV VACCINE SO CHALLENGING. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2022, 29 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: USING IMAGING TECHNOLOGY TO MEASURE THE HIV RESERVOIR IN ORDER TO TARGET AND POTENTIALLY ERADICATE THE HIV RESERVOIR, THE MAIN BARRIER TO A CURE, SCIENTISTS FIRST NEED TO DISCOVER WHERE EXACTLY HIV HIDES OUT. ALONG WITH HIS TEAM, AMFAR GRANTEE DR. TIMOTHY HENRICH, OF THE AMFAR INSTITUTE FOR HIV CURE RESEARCH AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, RECENTLY BECAME THE FIRST TO DEVELOP A METHOD OF USING PET IMAGING TO DIRECTLY ASSESS WHICH TISSUES IN LIVE HUMANS HARBOR THE GREATEST BURDEN OF VIRUS. HE REPORTED FURTHER WORK BY HIS TEAM, DESCRIBING HOW THE HIV RESERVOIR SHIFTS LOCATION OVER THE COURSE OF LONG-TERM TREATED HIV AND NEW METHODS OF MEASURING HIV ACTIVITY INSIDE LYMPH NODES IN REAL TIME. THE STUDY, PUBLISHED IN THE PRESTIGIOUS JOURNAL NATURE COMMUNICATIONS, HELPS FURTHER IDENTIFY AND CHARACTERIZE THE HIV RESERVOIR LOCATED IN PARTS OF THE BODY INACCESSIBLE TO ROUTINE SAMPLING BY PROVIDING A NON-INVASIVE WAY OF MEASURING THE TISSUE-WIDE BURDEN OF HIV OVER TIME. REVIVING THE "SHOCK AND KILL" APPROACH TO CURE HIV ANOTHER AMFAR-FUNDED STUDY WAS PUBLISHED IN NATURE COMMUNICATIONS IN JANUARY : DR. JEROME ZACK, OF UCLA, AND HIS TEAM SHARED THEIR FINDINGS ABOUT AN INNOVATIVE REFINEMENT TO THE "SHOCK AND KILL" APPROACH, WHICH SHOCKS THE VIRUS OUT OF LATENCY AND MAKES INFECTED CELLS VISIBLE TO THE IMMUNE SYSTEM FOR KILLING. THERE IS A LONG HISTORY OF ATTEMPTS AT SHOCK AND KILL THAT HAVE MET WITH LIMITED SUCCESS. ON THE ONE HAND, THE "SHOCK" ARM OF THE STRATEGY, KNOWN AS A LATENCY-REVERSING AGENT (LRA), HAS BEEN EITHER SAFE BUT INEFFECTIVE, OR EFFECTIVE BUT UNSAFE. IN ADDITION, THE "KILL" ARM OF THE APPROACH HAS BEEN AT BEST ONLY MODERATELY EFFECTIVE. DR. ZACK CREATED AN ANALOG OF A POTENT LRA, BRYOSTATIN, WHICH IS OTHERWISE TOXIC FOR HUMAN USE, CALLED SUW133, KNOWN TO BE ABLE TO INDUCE THE DEATH OF A SUBSET OF HIV-INFECTED CELLS. THE RESEARCHERS COMBINED SUW133 WITH A KILL AGENT IN THE FORM OF NATURAL KILLER (NK) CELLS AND TESTED IT IN HUMANIZED MICE. FOUR OUT OF THE 10 MICE TREATED WITH THE COMBINATION EXPERIENCED NO REBOUND OF HIV, PROVIDING RENEWED PROMISE THAT THE "SHOCK AND KILL" APPROACH CAN BE REFINED AND POTENTIALLY REVIVED. |
| FORM 990, PART III, LINE 4B | TREAT ASIA ALSO PARTICIPATED IN: THE 24TH BANGKOK INTERNATIONAL SYMPOSIUM ON HIV MEDICINE IN JANUARY 2022; THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) IN FEBRUARY; THE PEPFAR REGIONAL OPERATIONAL PLAN (ROP) VIRTUAL PLANNING MEETINGS (ASIA REGION) IN MAY; AND THE WORLD HEPATITIS SUMMIT AND THE SEVENTH ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC), BOTH IN JUNE; AND THE INTERNATIONAL WORKSHOP ON HIV PEDIATRICS 2022 IN JULY. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICE ACCOMPLISHMENTS: | PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH AND GLOBAL HIV/AIDS PROGRAMS, EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, ADVOCATE HARM REDUCTION POLICIES AIMED AT REDUCING THE TRANSMISSION OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. ENDING THE HIV EPIDEMIC IN THE U.S. THROUGHOUT THE YEAR, THE AMFAR POLICY TEAM WORKED CLOSELY WITH MEMBERS OF THE BIDEN ADMINISTRATION, THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), NATIONAL INSTITUTES OF HEALTH (NIH), AND THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC AND DISCUSS POLICY INITIATIVES. THIS INCLUDED MULTIPLE ADVOCACY MEETINGS, COLLABORATIVE EVENTS, AND CONSULTATIONS. THE POLICY TEAM MET WITH THE DEPUTY DIRECTOR FOR HEALTH AND LIFE SCIENCES, WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY, AND DISCUSSED ISSUES INCLUDING THE ADVANCEMENT OF WOMEN IN SCIENCE AND THE RESPONSE TO THE COVID AND OPIOID PANDEMICS. THE TEAM ALSO MET WITH THE CDC TO DISCUSS THE NEW MULTI-BILLION-DOLLAR PREP PROGRAM. THE POLICY OFFICE PARTICIPATED IN NUMEROUS WHITE HOUSE MEETINGS TO DISCUSS THE ADDITION OF A QUALITY OF LIFE INDICATOR TO THE NEWLY RELEASED NATIONAL HIV/AIDS STRATEGY; PROVIDE INPUT ON THE PRESIDENT'S PROPOSED BUDGET TO SUPPLEMENT OPIOID/HIV HARM REDUCTION SERVICES; AND CONTRIBUTE GUIDANCE ON THE ESTABLISHMENT OF A NEW AGENCY FOR HEALTH INNOVATION, ARPA-H. AMFAR POLICY STAFF WORKED WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES ON FY23 FUNDING FOR BOTH DOMESTIC AND GLOBAL HIV PROGRAMS. MONKEYPOX PUBLIC HEALTH EMERGENCY IN THE SPRING OF 2022, IN RESPONSE TO THE MONKEYPOX (NOW KNOWN AS MPOX) OUTBREAK IN PARTS OF EUROPE AND THE U.S., THE PUBLIC POLICY OFFICE WAS A CO-PRESENTER WITH THE WHITE HOUSE NATIONAL MONKEYPOX RESPONSE DEPUTY COORDINATOR DEMETRE DASKALAKIS DURING MULTIPLE HIGH-LEVEL MEETINGS. IN JULY, AMFAR STAFF ALSO PARTNERED WITH THE O'NEILL INSTITUTE AT GEORGETOWN LAW TO PUBLISH A CALL TO ACTION TO ADDRESS THE OUTBREAK AS A PUBLIC HEALTH EMERGENCY (MONKEYPOX AND MENINGOCOCCAL DISEASE OUTBREAKS SIGNAL NEW HEALTH THREATS FOR COMMUNITIES HEAVILY IMPACTED BY HIV AND DEMAND IMMEDIATE ACTION). IN THAT POLICY BRIEF, AMFAR INCLUDED A MODELING ANALYSIS THAT PREDICTED MPOX DIAGNOSES IN THE U.S. WOULD INCREASE TO 11,311 BY AUGUST 4. EIGHT DAYS AFTER THE ORIGINAL PROJECTION, THE CASES HAD RISEN TO 11,177, UNDERSCORING THE TWO INSTITUTIONS' PRESCIENT SENSE OF URGENCY. AMFAR AND THE O'NEILL INSTITUTE FOLLOWED UP WITH TWO SUPPLEMENTAL BRIEFS, TACKLING MPX IN BLACK AND LATINO COMMUNITIES AND MPX RESEARCH GAPS: WHAT REMAINS UNKNOWN. ALONG WITH DELIVERING SEVERAL PRESENTATIONS FOR POLICY MAKERS AND COMMUNITY ADVOCATES, AMFAR'S GREG MILLETT, M.P.H., VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY, ALSO CO-AUTHORED TWO EDITORIALS IN LEADING PEER-REVIEWED SCIENTIFIC JOURNALS, THE BMJ AND AMERICAN JOURNAL OF PUBLIC HEALTH. IN ADDITION, THE POLICY TEAM WAS INTERVIEWED BY REUTERS, NPR, AND NBC NEWS ABOUT THE MPOX OUTBREAK. ON THE RESEARCH FRONT, AMFAR AWARDED FUNDING TO TWO SURVEY-BASED STUDIES TO ASSESS THE IMPACT OF MPOX ON MSM IN NEW YORK CITY, THE EPICENTER OF THE U.S. OUTBREAK, IN ORDER TO PROVIDE KNOWLEDGE ABOUT MPOX AND DEVELOP TARGETED INTERVENTIONS. THE COVID-19 PANDEMIC IN 2022, AMFAR CONTINUED TO HIGHLIGHT THE IMPACT OF COVID-19 ON THE HIV RESPONSE BOTH DOMESTICALLY AND GLOBALLY, AND THE INEQUITABLE DOMESTIC IMPACT OF COVID-19. POLICY STAFF PRESENTED ON COVID-19 AT THE CDC AND PRESENTED ON THE SIMILARITIES OF COVID AND HIV AT THREE UNIVERSITIES (NYU, GEORGETOWN, AND UNC CHAPEL HILL). THE TEAM ALSO MODERATED A PANEL FOR A GEORGETOWN LAW SCHOOL MEETING ON THE HIV CARE CONTINUUM AFTER COVID-19. IN ADDITION, THE TEAM MET WITH THE DIRECTOR OF THE WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY (OSTP) TO DISCUSS COVID-19 AND OTHER PUBLIC HEALTH ISSUES. HIV AND THE OPIOID EPIDEMIC AMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. ITS OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) IS A FREE WEB PLATFORM DESIGNED TO SUPPORT LAWMAKERS, COMMUNITIES, AND ADVOCATES IN MAKING INFORMED DECISIONS ABOUT THE OPIOID EPIDEMIC AND ITS IMPACT ON HIV AND HEPATITIS C. THE SITE IS A WINDOW INTO THE OPIOID EPIDEMIC UNFOLDING IN EVERY AMERICAN'S BACKYARD. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES. IN 2022 THE POLICY TEAM MET WITH THE OFFICE OF EXTERNAL AFFAIRS AT HHS AND PRESENTED AMFAR'S OPIOID AND HEALTH INDICATORS DASHBOARD. AMFAR STAFF ALSO PARTICIPATED IN SAMHSA'S REGION 5 OPIOID TASKFORCE. GLOBAL HEALTH THE AMFAR POLICY OFFICE MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES INCLUDING ATTENDING PEPFAR COUNTRY OPERATIONAL PLAN MEETINGS (FOR BOTSWANA, CAMEROON, COTE D'IVOIRE, ESWATINI, KENYA, MALAWI, SOUTH AFRICA, TANZANIA, ZAMBIA, AND ZIMBABWE), THE GLOBAL FUND PARTNERSHIP FORUM, AND THE UN HIGH-LEVEL MEETINGS ON HIV/AIDS. POLICY STAFF ENGAGE IN ADVOCACY WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES TO SECURE STRONG GLOBAL HIV BUDGETS AND CLOSELY TRACK AND RESPOND TO NEW GLOBAL HEALTH POLICIES. ADDITIONALLY, AMFAR PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN SEVEN COUNTRIES. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY WITH DUTY BEARERS. AMFAR CONDUCTED A THREE-DAY TRAINING WORKSHOP IN SOUTH AFRICA FOR COMMUNITY-LED MONITORING PROGRAMS IN SOUTH AFRICA, ZIMBABWE, UGANDA, AND MALAWI. IN THE U.S., THE TEAM ALSO MET WITH OFFICE OF GLOBAL AIDS COORDINATOR STAFF ON BEST PRACTICES ON COMMUNITY-LED MONITORING FUNDING AND PROJECT STRUCTURES. THE POLICY TEAM HELD MEETINGS WITH USAID, CDC, AND OTHERS TO DISCUSS A VARIETY OF TOPICS, INCLUDING PEPFAR RECENCY TESTING, STRATEGIES FOR KEY POPULATIONS, COMMUNITY-LED MONITORING, AND DATA-DRIVEN ADVOCACY, AMONG OTHERS. THE TEAM ALSO WORKED TO GARNER BIPARTISAN SUPPORT FROM SENATE OFFICES FOR GLOBAL HIV FUNDING IN ADVANCE OF GLOBAL FUND'S SEVENTH REPLENISHMENT, AND WORKED WITH SENATE MAJORITY LEADER SCHUMER'S NOMINATION TEAM TO CONFIRM DR. JOHN NKENGASONG AS THE U.S. GLOBAL AIDS COORDINATOR. IN AUGUST 2022, AMFAR STAFF PUBLISHED THREE ARTICLES IN ACADEMIC JOURNALS WITH FAR-REACHING POLICY IMPLICATIONS. -TELEHEALTH SERVICES: IMPLICATIONS FOR ENHANCING SEXUALLY TRANSMITTED INFECTION PREVENTION IN THE JOURNAL SEXUALLY TRANSMITTED DISEASES (ONLINE AHEAD OF PRINT). THE AUTHORS PRESENT CONSIDERATIONS FOR TELEHEALTH AND HOW IT CAN CONTRIBUTE TO INCREASING HEALTH EQUITY BY OFFERING AN IMPORTANT COMPLEMENT TO AND, IN SOME CASES, SUBSTITUTE FOR IN-PERSON STI SERVICES FOR SOME POPULATIONS. -IN COMPETING HEALTH RISKS ASSOCIATED WITH THE COVID-19 PANDEMIC AND EARLY RESPONSE: A SCOPING REVIEW, PUBLISHED IN PLOS ONE, THE AUTHORS ANALYZE THE EARLY IMPACT OF COVID-19 ON HIV, TUBERCULOSIS, MALARIA, SEXUAL AND REPRODUCTIVE HEALTH, AND MALNUTRITION. -WHAT CAN WE LEARN FROM THE FIRST 100 DAYS OF THE MONKEYPOX OUTBREAK? IN THE BMJ DESCRIBES A PLAN OF ACTION FOR ADDRESSING THIS PUBLIC HEALTH THREAT, INCLUDING FILLING KEY KNOWLEDGE GAPS TO STEM TRANSMISSION, ANTICIPATING HOW THE PANDEMIC MAY UNFOLD, AND TRANSITIONING FROM DISCUSSIONS AROUND A NEW GLOBAL PUBLIC HEALTH ARCHITECTURE TO ITS IMPLEMENTATION. AMFAR ALSO CONTINUES TO PRODUCE REPORTS AND ISSUE BRIEFS ON A VARIETY OF GLOBAL HEALTH AND HIV-RELATED TOPICS. IN JUNE, THE POLICY TEAM PRODUCED A MAJOR REPORT, BLINDED BY OUR OWN DATA-RECENCY TESTING IN PEPFAR, THAT OUTLINED THE TECHNICAL AND SOMETIMES ETHICAL LIMITATIONS OF PEPFAR'S WELL-INTENTIONED STRATEGY TO RESPOND TO NEW TRANSMISSION "HOT SPOTS." ALSO IN JUNE, AMFAR RELEASED KEY POPULATIONS, SIZE ESTIMATES, AND PLANS IN COP22, WHICH POINTS OUT THE WAYS IN WHICH THE SIZES OF KEY POPULATIONS ARE UNDERESTIMATED AND PROVIDES GUIDANCE ABOUT HOW TO BEST ADDRESS FUNDING DISCREPANCIES THAT RESULT FROM THEM. |
| FORM 990, PART III, LINE 4C | DATA TRANSPARENCY AMFAR MAINTAINS THE PEPFAR MONITORING, EVALUATION, AND REPORTING (MER) DATABASE (MER.AMFAR.ORG). LAUNCHED IN DECEMBER 2018, THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. THE DATABASE COMPLEMENTS AMFAR'S PEPFAR DATABASE (COPSDATA.AMFAR.ORG), WHICH HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS PEPFAR DATA AND PREPARE FOR ADVOCACY INITIATIVES. LAUNCHED IN 2021, THE KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG) BRINGS TOGETHER AVAILABLE DATA ON KEY POPULATION DEMOGRAPHICS, EPIDEMIOLOGY, FUNDING, AND PROGRAMMING FROM UNAIDS, PEPFAR, AND THE GLOBAL FUND. THIS RESOURCE INCLUDES COUNTRY FACTSHEETS SHOWING HOW FUNDING HAS EVOLVED OVER TIME, AND, WHERE POSSIBLE, IDENTIFIES WHO IS RESPONSIBLE FOR IMPLEMENTING KP PROGRAMMING IN THE PEPFAR PROGRAM. THIS PROJECT COMPLEMENTS EXISTING WORK IN THE MER AND COPS DATABASES AND IS A KEY TOOL FOR KP ADVOCATES. XXIV INTERNATIONAL AIDS CONFERENCE AND OTHER CONFERENCES AMFAR'S POLICY OFFICE PARTICIPATED IN THE XXIV INTERNATIONAL AIDS CONFERENCE IN MONTREAL, CANADA, THE WORLD'S LARGEST CONFERENCE ON HIV AND AIDS. DELEGATES CAME TOGETHER IN-PERSON AND VIRTUALLY TO HEAR ABOUT AND DISCUSS THE LATEST HIV RESEARCH FINDINGS, AS WELL AS PROGRAMMATIC, ADVOCACY, AND POLICY ISSUES. AT THE CONFERENCE AMFAR STAFF AUTHORED NINE ABSTRACTS, COVERING TOPICS SUCH AS TRANS INCLUSION IN HIV NATIONAL STRATEGIES, THE USE OF COMMUNITY-LED MONITORING IN SOUTH AFRICA AND MALAWI, AND THE QUALITY AND IMPLICATIONS OF PEPFAR'S PERFORMANCE TARGETS, AMONG OTHERS. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 12C | EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. |
| FORM 990, PART VI, SECTION B, LINE 15 | AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN AUGUST OF 2020 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AS OF JUNE 2022, AMFAR IS IN THE PROCESS OF REVIEWING ALL EXECUTIVE AND STAFF SALARIES AND HAS COMMISSIONED AN INDEPENDENT THIRD PARTY COMPENSATION CONSULTANT TO PROVIDE AN UPDATED REPORT. |
| FORM 990, PART VI, SECTION C, LINE 19 | AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. |
| PART IX, LINES 1 & 3 | THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F. |
| Software ID: | |
| Software Version: |